GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 689
- Registration Number
- NCT05502341
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
🇰🇷Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 792
- Registration Number
- NCT05502237
- Locations
- 🇦🇷
Clínica Viedma, Viedma, Argentina
🇦🇹Klinikum Klagenfurt am Woerthersee, Klagenfurt Am Woerthersee, Austria
🇺🇸Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT05458102
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸Collaborative Neuroscience Research, LLC., Long Beach, California, United States
🇺🇸Triple O Research Institute, P.A., West Palm Beach, Florida, United States
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 540
- Registration Number
- NCT05382299
- Locations
- 🇺🇸
Florida Cancer Specialists - North Region Research Office,521 North Lecanto Highway, Lecanto, Florida, United States
🇺🇸Florida Cancer Specialists,1100 Goodlette Road, Naples, Florida, United States
🇺🇸Florida Cancer Specialists,681 4th Avenue North, Naples, Florida, United States
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 440
- Registration Number
- NCT05382286
- Locations
- 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Magee-Womens Hospital of UPMC,5115 Centre Avenue, Pittsburgh, Pennsylvania, United States
Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 77
- Registration Number
- NCT05330429
- Locations
- 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Virginia Cancer Specialists, PC, Arlington, Virginia, United States
🇺🇸Seattle Cancer Care Alliance (SCCA), Seattle, Washington, United States
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 21
- Registration Number
- NCT05281510
- Locations
- 🇿🇦
FRESH Clinical Research Site: Females Rising through Education, Support and Health, Umlazi, South Africa
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 193
- Registration Number
- NCT05186974
- Locations
- 🇭🇰
Queen Elizabeth Hospital, Hong Kong, Hong Kong
🇲🇾Institut Kanser Negara, Putrajaya, Malaysia
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT05165771
Study of Sacituzumab Govitecan in Patients With Solid Tumor
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT05119907
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, China
🇨🇳Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China
🇨🇳Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China